SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not...

SpeeDx receives FDA clearance for Mycoplasma genitalium product SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx’s ResistancePlus® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United...